Диссертация (1140172), страница 15
Текст из файла (страница 15)
– 2008. – Vol. 48. – Р. 157–165.39. Brenner SS, Herrlinger C, Dilger K, Mürdter TE, Hofmann U, Marx C, Klotz U.Influence of age and cytochrome P4502C9 geno-type on the steady-state disposition ofdiclofenac and celecoxib // Clin Pharmacokinet. – 2003. – Vol. 42.
– Р. 283–292.40. Davies E, Green C, Taylor S. et al. Adverse drug reactions in hospital in-patients: aprospective analysis of 3695 patient-episodes // PLoS One. – 2009. – Vol. 4, N 2. – Р.4439.41. Dedhiya S., Hancock E., Craig B. et al. Incident use and outcomes associated withpotentially inappropriate medication use in older adults // J Am Geriatr. Pharmacother. –2010. – Vol.
8, N 6. – Р. 562–570.42. Dilger K, Hofmann U, Klotz U. Enzyme induction in the elderly: effect ofrifampicin on pharmacokinetics and pharmacody-namics of propafenone // ClinPharmacol Ther. – 2000. – Vol. 67. – Р. 512–520.43. Edholm M, Gil Berglund E, Salmonson T. Regulatory aspects of pharmacokineticprofiling in special populations: a European perspective // Clin Pharmacokinet. – 2008. –Vol. 47. – Р. 693–701.10644. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M.
Antipyrine as aprobe for human oxidative drug metabolism: identification of the cytochrome P450enzymes catalyzing 4-hy-droxyantipyrine, 3-hydromethylantipyrine, and norantipyrineformation // Clin Pharmacol Ther. – 1996. – Vol. 59.
– Р. 613–623.45. Faber MS, Fuhr U. Time response of cytochrome P4501A2 activity on cessation ofheavy smoking // Clin Pharmacol Ther. – 2004. – Vol. 76. – Р. 178–184.46. Feng Y, Pollock BG, Ferrell RE, Kimak MA, Reynolds, CFIII, Bies, RR.Parоxetine: population pharmacokinetics analysis in late-life depression usinge sparseconcentration sampling // Br J Clin Pharmacol. – 2006. – Vol.
61. – Р. 558–569.47. Fiss T., Dreier A., Meinke C. et al. Frequency of inappropriate drugs in primarycare: analysis of a sample of immobile patients who received periodic home visits //Age Aging. – 2011. – Vol. 40, N 1. – Р. 66–73.48. Food and drug administration: The FDA Safety Information and Adverse EventReportingProgram.URL:http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm172268.htm. Access date: 02.04.2012.49. Francis L, Bonilla E, Soforo E, Neupane H, Nakhla H, Fuller C, Perl A.
Fatal toxicmyopathy attributed to propofol, methylprednisolone, and cyclosporine after priorexposure to colchicine and simvastatin // Clin Rheumatol. – 2008 Jan. – Vol. 27, N 1. –Р. 129–131.50. Frassetto LA, Poon S, Tsourounis C, Valera C, Benet LZ. Effects of uptake andefflux transporter inhibition on erythromycin breath test results // Clin Pharmacol Ther.–2007. – Vol. 81. – Р. 828–832.51. Fromm MF, Dilger K, Busse D, Kroemer HK, Eichelbaum M, Klotz U. Gut wallmetabolism of verapamil in older people: effects of rifampicin-mediated enzymeinduction // Br J Clin Pharmacol. – 1998.
– Vol. 45. – Р. 247–255.10752. Gallagher P., Ryan C., Byrne S., Kennedy J., O’Mahony D. STOPP (Screening Toolof Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to RightTreatment). Consensus validation // Clin Pharmacol Ther. – 2008. – Vol. 46, N 2. – Р.72–83.53. Gallagher P.F., O’Connor M.N., O’Mahony.
Prevention of potentially inappropriateprescribing for elderly patients: a randomized controlled trial using STOPP/STARTcriteria // Clin Pharmacol Ther. – 2011. – Vol. 89. – Р. 845–854.54. Galteau MM, Shamsa F. Urinary 6beta-hydroxycortisol: a validated testforevaluating drug induction or drug inhibition mediated through CYP3A in humansandin animals // Eur J Clin Pharmacol. – 2003 Dec. – Vol. 59, N 10. – Р. 713–733.55.
Garfinkel D., Zur-Gil S., Ben-Israel J. The war against polypharmacy: a new costeffective geriatric-palliative approach for improving drug therapy in disabled elderlypeople // Isr Med Assoc J. – 2007. – Vol. 9, N 6. – Р. 430–434.56. George M, Shewade DG, Kumar SV, Adithan C. Effect of anti-tuberculosis therapyon polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug //Indian J Pharmacol. – 2012 Jul-Aug. – Vol. 44, N 4.
– Р. 485–488.57. Glassman P., Simon B., Belperio P., Lanto A. Improving recognition of druginteractions benefits and barriers to using automated drug alerts // Med Care. – 2002. –Vol. 40, N 12. – Р. 1161-1171.58. Goltz L., Kullak-UblickG., Kirch W. Potentially inappropriateprescribing forelderly outpatients in Germany: a retrospective claims data analysis // Int J ClinPharmacol Ther. – 2012. – Vol. 50, N 3. – Р. 185-194.59. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, HaehnerDaniels B, Hall SD. The effect of age, sex, and rifampicin administration on intestinaland hepatic cytochrome P4503A activity // Clin Pharmacol Ther.
– 2003. – Vol. 74. – Р.275–287.10860. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI.Effect of age, gender, and obesity on mida-zolam kinetics // Anaesthesiology. – 1984. –Vol. 61. – Р. 27–35.61. Greenblatt DJ, Divoll M, Abernethy DR, Harmatz JS, Shader RI. Antipyrinekinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizingcapacity // J Pharmacol Exp Ther. – 1982. – Vol. 220.
– Р. 120–126.62. Greenblatt DY, Shader RI, Harmatz JS. (1989). Implications of altered drugdisposition in the eldery: studies with benzodiazepines // J Clin Pharmacol. – 1989. –Vol. 29. – Р. 866–872.63. Hamilton H., Gallagher P., Ryan C. et. al. Potentially inappropriate medicationsdefined by STOPP criteria and the risk of adverse drug events in older hospitalizedpatients // Arch Intern Med. – 2011.
– Vol. 171. – Р. 1013–1019.64.HämmerleinA,DerendorfH,LowenthalDT.Pharmacokineticandpharmacodynamic changes in the elderly. Clinical implications // Clin Pharmacokinet. –1998. – Vol. 35. – Р. 49–64.65. Hanlon J., Schmader K., Koronkowski M. et al. Adverse drug events in high riskolder outpatients // J Am Geriatr Soc. – 1997. – Vol.
45. – Р. 945–948.66. Harper KW, Collier PS, Dundee JW, Elliott P, Halliday NJ, Lowry KG. Age andnature of operation influence the pharmacokinetics of midazolam // Br J Anaesth. –1985. – Vol. 57. – Р. 866–871.67. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly // BestPract Res Clin Gastroenterol. – 2001. – Vol.
15. – Р. 897–918.68. Hovstadius B, Hovstadius K, Astrand B, Petersson G. Increasing polypharmacy - anindividual-based study of the Swedish population 2005-2008 // BMC ClinPharmacol. –2010 Dec. – Vol. 2. – Р. 10-16.10969. Hubbard RE, O’Mahony MS, Calver BL, Woodhouse KW. Plasma esterases andinflammation in ageing and frailty // Eur J Clin Pharmacol. – 2008. – Vol. 64. – Р.
895–900.70. Hung IF, Wu AK, Cheng VC, Tang BS, To KW, Yeung CK, Woo PC, Lau SK,Cheung BM, Yuen KY. Fatal interaction between clarithromycin and colchicine inpatients withrenal insufficiency: a retrospective study // Clin Infect Dis. –2005 Aug 1. –Vol. 41, N 3. – Р. 291–300.71. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity ofhuman hepatic CYP3A // Biochem Pharmacol.
– 1992. – Vol. 44. – Р. 275–283.72. Hu S., Capezuti E., Foust J. et al. Medication discrepancy and potentiallyinappropriate medication in older Chinese-American home-care patients after hospitaldischarge. J Am Geriatr Pharmacother // 2012. – Vol. 10, N 5. – Р. 284–295.73. Ishizawa Y, Yasui-Furukori N, Takahata T, Sasaki M, Tateishi T.
The effect ofaging on the relationship between the cytochrome P4502C19 genotype and omeprazolepharmacokinetics // Clin Pharmacokinet. – 2005. – Vol. 44. – Р. 1179–1189.74. James OF. Parenchymal liver disease in the elderly // Gut. – 1997. – Vol. 41. – Р.430–432.75. Jetter A, Kinzig-Schippers M, Skott A. Cytochrome P450 2C9 phenotyping usinglow-dose tolbutamide. Eur J Clin Pharmacol // 2004 May. – Vol. 60, N 3.
– Р. 165–171.76. Joy MS, Dornbrook-Lavender K, Blaisdell J, Hilliard T, Boyette T, Hu Y, Hogan SL,Candiani C, Falk RJ, Goldstein JA. CYP2C9 genotype and pharmacodynamic responsesto losartan in patients with primary and secondary kidney diseases // Clin Pharmacol. –2009 Sep. – Vol. 65, N 9. – Р. 947–953.77. Klotz U.
Effect of age on pharmacokinetics and pharmacody-namics in man // InternJ Clin Pharmacol Ther. – 1998. – Vol. 36. – Р. 581–585.11078. Klotz U. Effect of aging on the pharmacokinetics of gastroin-testinal drugs. In:Pilotti A, Malferthheiner P, Holt PR(eds.) Aging and the Gastrointestinal Tract //Interdisciplinary Topics in Gerontology. – 2003. – Vol. 32. – Р. 28–39.79. Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs:pharmacokinetic and therapeutic implications // Clin Pharmacokinet.
– 2007. – Vol. 46.– Р. 271–279.80. Klotz U. The elderly–a challenge for appropriate drug treatment // Eur J ClinPharmacol. – 2008. – Vol. 64. – Р. 225–226.81. Klotz U. Pharmacokinetics and drug metabolism in the elderly // Drug Metab Rev. –2009. – Vol. 41, N 2. – Р. 67–76.82. Klotz U, Fischer C, Müller-Seydlitz P, Schulz J, Müller WA.
Alterations in thedisposition of differently cleared drugs in patients with cirrhosis // Clin Pharmacol Ther.– 1979. – Vol. 26. – Р. 221–227.83. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pumpinhibitors // Basic Clin Pharmacol Toxicol. – 2004. – Vol. 95. – Р. 2–8.84. Kurnik D, Wood AJ, Wilkinson GR.
The erythromycin breath test reflects Pglycoprotein function independently of cytochrome P450 3A activity // Clin PharmacolTher. – 2006. – Vol. 80. – Р. 228–234.85. Le Couteur DG, Fraser R, Hilmer S, Rivory LP, McLean AJ. The hepatic sinusoidin aging and cirrhosis: effects on hepatic substrate disposition and drug clearance // ClinPharmacokinet. – 2005.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
